His recent research has aimed at developing newborn screening detection and effective therapy to prevent central nervous system pathology for LSD patients. Importantly, this research continues as a collaborative effort with many colleagues within the unit and worldwide. John has supervised 17 PhD students, published 282 papers in international journals and books, and holds more than 30 patents. John has also been a major contributor to the establishment of Lysosomal Diseases Australia (LDA – an umbrella organization established to increase public, professional and institutional awareness of LSD), the Global Organisation for Lysosomal Disorders (GOLD – formed to globally unify professionals, patients and biotechnology companies to improve education about LSD and to achieve early diagnosis and effective therapies), and the Howard Florey Lysosomal Diseases Therapeutic Centre in Adelaide to progress the introduction of therapies into clinical practice.